Psylin will use both companies’ databases and technology to evaluate potential peptide hormone therapies.
PsychoGenics collaborated with Amylin Pharmaceuticals to form Psylin Neurosciences, a new company that will focus on the discovery and development of peptide hormones for the treatment of psychiatric disorders.
“The creation of Psylin affords both companies the opportunity to pursue a new area of research, while maintaining their corporate focus,” says Emer Leahy, Ph.D., president and CEO of PsychoGenics.
Both companies participated equally in a Series A financing of Psylin that is anticipated to fund the company for the next two years.
Under this new venture, Psylin will have access to molecules in Amylin’s polypeptide hormone library, Phormol™, and to PsychoGenics’ drug discovery technologies. Psylin will also have the right to develop a number of drug candidates emerging from this collaboration.